Aug 07, 2019 / 01:00PM GMT
Mark Anthony Massaro - Canaccord Genuity Corp., Research Division - Senior Analyst
We're going to get started. It's 9:00. Very pleased to welcome back Exact Sciences. Many of you know Exact and have seen their commercials. They sell Cologuard. It's a tremendous noninvasive colon cancer screening test. The company has really been a spectacular stock. They've been one of our top picks for the last 3 consecutive years. The returns have been outstanding. Exact remains a top pick, and they just came off a very strong Q2. They also came off a surprising announcing to acquire Genomic Health, which was just last week. So I'm really pleased to welcome back Exact's CFO, Jeff Elliott.
Thanks, Jeff, for being here.
Jeffrey T. Elliott - Exact Sciences Corporation - CFO
Thanks, Mark. It's good to be back.
Questions and Answers:
Mark Anthony Massaro - Canaccord Genuity Corp., Research Division - Senior AnalystAll right. So why don't we start with the Genomic Health acquisition? You named a long list of reasons to